PROpranolol for Cerebral Hemorrhage-ASsociated pnEumonia (PRO-CHASE)

Inclusion Criteria:

1. Age 18 years older and less than 80 years.

2. Onset of new neurological deficits within≤24 hours at the time of randomization

3. CT scan demonstrates supratentorial parenchymal hemorrhage and volume ofhematoma≥10ml .

4. Initial NIHSS score of 11 or greater and less than 25 scores.

5. Initial GCS score (aggregate of verbal, eye, and motor response scores) of 8 orgreater at time of enrollment.

6. Admission without infection signs.

7. Signed and dated informed consent by the subject, legally authorized representative,or surrogate obtained.

Exclusion Criteria:

1. Subjects is considered a candidate for immediate surgical intervention by theneurosurgery service, including surgical evacuation of hematoma, decompressivecraniectomy, minimally invasive aspiration of hematoma, and ventricular shunt orexternal ventricular drainage for intracerebral hemorrhage into the ventricle.

2. Patients with primary intraventricular hemorrhage or cerebral hemorrhage due to adefinite cause, such as trauma, vascular malformation, aneurysm, coagulopathy,anticoagulant or antiplatelet drugs, thrombolytic therapy, post-infarctionhemorrhagic transformation, hematologic disease, moyamoya disease, primary ormetastatic tumor, venous sinus thrombosis, vasculitis, etc.

3. Previous stroke or pre-onset motor disability (mRS≥1)

4. Pregnancy or parturition within previous 30 days or active lactation.

5. Use of beta blockers (propranolol, metoprolol, sotalol, carvedilol, bisoprolol,atenolol, esmolol, etc.) or reserpine within the last 30 days.

6. Bronchial asthma or chronic obstructive pulmonary disease

7. Cardiogenic shock or severe or acute heart failure.

8. Degree II-III atrioventricular block or sinus bradycardia or heart rate ≤65/min.

9. Known sensitivity to propranolol.

10. Severe hepatic or renal insufficiency

11. History of Malignancy

12. Currently participating in other interventional clinical trials.

13. Immunosuppressant therapy or known immunosuppression.